Support and Resistance Levels
Past performance
About Suven Life Sciences Ltd Suven Life Sciences Limited, originally established as Suven Pharmaceuticals Ltd in 1989, is a clinical-stage biopharmaceutical company dedicated to developing and commercializing novel therapeutics for neurodegenerative disorders. With a focus on CNS therapies, Suven operates through its wholly owned subsidiary, Suven Neurosciences, Inc. in the USA, managing clinical development from Phase 2 studies. The company provides Contract Research and Manufacturing Services (CRAMS) for the global life sciences industry, offering custom synthesis, process R&D, and contract manufacturing of intermediates, APIs, and formulations. Suven's strategic shift from project-based to relationship-based business underscores its capacity for innovation and collaboration.
The company has made significant strides in drug discovery, particularly in CNS-based programs targeting cognition, depression, and pain management, with a robust pipeline of 14 molecules. Suven's commitment to R&D is evident, with substantial investments in CNS therapies and collaborations, such as the licensing agreement with Taro Pharmaceuticals for Malathion lotion. The demerger of its CRAMS business into Suven Pharmaceuticals Limited in 2019 further streamlined its operations, allowing Suven Life Sciences to concentrate on its core biopharmaceutical pursuits.